Growth Decision Architecture™

Management brings a deal to the board, and within a few meetings the conversation is about price. What are we paying? What multiple does that imply? How does it compare with the last deal in the sector?

Those are fair questions, but they are also the questions least likely to determine whether the acquisition pays back.

Every acquisition is underwritten against a promise: a return, a timeframe, and the assumptions required for both. Whether the company earns that return depends on who the buyer is, how the business will be owned after close, how much of it will be integrated, and whether the parent can absorb a miss.

None of that shows up in the purchase price.

Price shows a board how much capital it is committing. It says almost nothing about how much of the enterprise is at risk, how much work the target brings with it, or whether this buyer is the right owner for what it is buying.

Those answers arrive before valuation, or they arrive too late. By the time a number is on the table, a board is defending a plan instead of testing one.

Six questions, then a decision

The Growth Decision Architecture™ is a set of six questions a board should answer before the conversation turns to price, followed by a decision with more than two possible answers.

The first four settle the growth strategy and whether the company can pursue it:

1. Why grow at all?

2. How far from the core?

3. How do we enter, and who should own it?

4. Who is going to run this?

The last two test a specific acquisition, and they apply only after acquisition has emerged as the preferred path:

5. Are we buying scale, or buying work?

6. What survives when the plan doesn't?

A board that has not answered the first four has no basis for the last two. A board that skips the last two is approving a strategy, not a deal.

The board sets the objective. Management builds the plan.

One principle governs all six questions. The board says why growth is required and what result it has to produce. Then management builds the plan that gets there.

The board should not determine the growth plan. Management does, with guidance from the board. The moment the board specifies the plan, it becomes the board's plan instead of management's. A board that wrote the plan has no independent position from which to test it when it underperforms. It will defend, not challenge.

The boundary gets crossed in predictable ways:

• The board names a mechanism before it names an outcome. "Go make an acquisition."
• Management adopts a growth number with no reason behind it. A 5% target that exists because 5% is what the KPIs and bonuses were built around, and no strategic question has been answered.
• An outside consultant says the company has to be in a market. The board approves without asking whether the company has any experience in that kind of business.

A board can check which side of the line it is on with two questions. Is the plan in front of us management's plan or ours? And if this plan underperforms, will we be able to challenge it, or will we be defending it?

Question 1: Why grow at all?

A stated growth problem is often something else: a margin problem, a portfolio problem, a capability problem, a market-access problem, a capital-allocation problem, or an ownership problem.

Each requires a different response, and an acquisition solves only some of them. The board's first job is to name the problem before anyone selects a mechanism.

Why is growth necessary, and what specific result must it produce? What happens if the company does not grow? Why is this a better use of capital than improving the core business, pruning the portfolio, or returning the money to shareholders?

In 2008, Teradyne was a publicly traded semiconductor automated test equipment manufacturer with roughly $1 billion in annual revenue and 3,600 employees. Their necessity for growth and diversification came from a market running out of room. Semiconductor capital equipment is a mature industry that consolidates toward two or three suppliers per category.

When I joined, there were four semiconductor test companies, and the company was about to acquire the fourth. Both management and the board concluded the company had to grow outside its core. That is what a stated reason looks like.

Success gets defined in writing, in the same meeting where the board names the growth imperative. A board that has not defined success in advance will define it after the fact, using whichever measure is most flattering. If the stock rose on announcement, the deal worked. If the goodwill was later written down, it didn't.

One deal can produce both results, so a board that picks its measure afterward is not discovering whether the deal worked. It is deciding what to call it.

Acquisition success has five dimensions, and the board defines all of them before approval:

• Financial. Return on invested capital, earnings contribution, cash generation, margin.
• Market. Shareholder return, valuation multiple, investor confidence.
• Operating. Customer retention, revenue quality, integration progress, realized gains from combination.
• Strategic. Market entry, capability acquired, competitive position, channel expansion.
• Governance. Clear accountability, early visibility into problems, the ability to intervene.

These measures do not move together. The company can meet its return target while customers leave, or enter the market the thesis promised while the stock falls on announcement.

The board can read four different verdicts on the same transaction: the announcement return, the impairment test, the operating results, and the strategic position. Unless the board has said in advance which of them counts, and by when, it will read whichever one supports the decision it already made.

The output of question one is written: the imperative, the intended result, the timing, the alternative use of capital, and the definition of success.

Question 2: How far from the core?

Strategic distance is measurable. Count how many of these change at once: product, customer, geography, channel, business model, technology, operations, regulatory exposure.

A near adjacency changes one or two. A far adjacency changes several, and the more that change simultaneously, the greater the burden of proof on management.

When the mandate at Teradyne was set, we drew the map. We were in automated test equipment for semiconductors. We could do something else in semiconductor equipment, something else in automation, something else in test, or other kinds of equipment.

We picked three arenas we were not in and went looking. Each direction changed a different set of dimensions, so we knew where the case had to be strongest.

The board's questions here:

• Which capabilities transfer, and which are missing?
• Is this arena attractive to this company specifically, or attractive in general?
• Would this smooth out our business cycle?
• Does the opportunity require ownership, or would access be sufficient?
• What must the company learn before making a larger commitment?

Distance is not a reason to say no. It is a reason to know what changes if we do this deal.

Question 3: How do we enter, and who should own it?

This is a two-part decision, and boards tend to skip both parts by assuming the answer is an acquisition.

The entry decision. There are 10 ways to pursue a growth opportunity, and they run in order of commitment:

1. Maintain the current strategy or return capital
2. Build organically
3. Incubate internally
4. Partner
5. License
6. Form a joint venture
7. Invest through corporate venture capital
8. Take a minority stake
9. Make a bolt-on acquisition
10. Make a transformational acquisition

At every rung above the first, the company gives up capital and optionality to gain control. Reversibility falls as commitment rises; the early rungs can be unwound, and the later ones cannot. Control rises the same way, and only at the top rungs does the company gain the right to direct the business.

The bottom rung is a decision, not the absence of one. A framework that cannot produce "do not grow" as an answer is not a decision framework. The question that identifies the right rung: what is the smallest commitment that would materially improve decision quality?

When the market is far from the core and the company knows little about it, a corporate venture investment can be the cheapest way to learn whether the company belongs there.

The ownership decision. When ownership is on the table, the question is who is the best owner for this business. Start with the company, not with yourself. What kind of owner does this business need next, given where its growth has to come from? Then ask whether we are that owner.

Sometimes the answer is a different kind of company in a different industry with a different reason to grow, and the board's job is to say so out loud before anyone bids.

Getting outbid is sometimes the better outcome.

When a competitor wants a target that fits us poorly, letting them win hands them the integration problem, the management turnover, and the distraction. The highest bidder, the nearest competitor, and the most enthusiastic buyer are all easy to mistake for the right owner, including when the eager buyer is us.

To describe the right owner, identify where the target's next stage of value will come from. There are three sources, and each one points to a different kind of owner:

• Standalone improvement: governance, management depth, pricing, working capital, reporting. The natural owner is a financial buyer, an operator-led investor, or the company itself remaining independent, because that value does not require another business to exist.
• Combination value: product integration, cross-sell, distribution, manufacturing scale. The natural owner is a strategic acquirer, because that value only appears inside a specific counterparty.
• Platform value: operating improvement plus repeated acquisitions and shared infrastructure. The natural owner is a sponsor-backed platform, because that value compounds across a sequence of deals rather than one.

The best owner is the one whose capabilities match the source of future value. A buyer that cannot say which of the three it is underwriting is not ready to say what it should pay.

Question 4: Who is going to run this?

Traditional diligence asks whether the target fits the acquirer, but the harder question runs the other way: does the acquirer fit the target?

The wrong owner can damage an attractive business: slow corporate processes, a governance model built for a different kind of company, an integration plan that removes what made the target good, incentives that drive the founding team to leave.

Too many diligence processes focus on legal and financial issues and never ask why the company is successful in the first place. If the answer is that it has a great channel, and the buyer does not do channels, someone has to say what the plan is.

The board must ask:

• Who owns the value-creation plan? Name the person.
• What work will stop, or receive less attention, and who will protect the base business?
• Have we executed this type of transaction before, and which parts of that experience transfer? Experience counts only when it has produced repeatable capability. Repetition alone guarantees nothing.
• Are we buying a scalable business, or do we need to assign a professional management team?

The cheapest answer to question four is the one given before a process starts.

At Teradyne, we looked at an early-stage robotics company whose founder was brilliant technically but understood little about how a manufacturing line in Asia works. The product was not adaptable, the cultural mismatch was large, and a strategic investor already held a right of first refusal. We decided not to pursue them.

That walk-away cost nothing, and it happened because we asked who was going to run this before we asked what it would cost.

Question 5: Are we buying scale, or buying work?

Price and relative size measure two different things. Price measures the capital committed. Relative size measures how much of the enterprise is exposed if the deal fails. A board needs to assess them separately.

Capital risk is measured against market value, cash flow, debt capacity, and the parent's ability to absorb a miss. Execution risk is driven by target maturity, founder dependency, management depth, integration burden, and buyer experience.

A deal can be small on the first measure and enormous on the second.

Compare a $20 million company run by its founder with a $200 million market leader with audited financials and a professional management team. Growing the $20 million company to $200 million takes far more investment, time, and management attention than buying the $200 million company does.

The founder-owned firm may not integrate well, and the cultural issues are the buyer's to solve. The market leader arrives with people. Make them VPs, put one on the board, give them the capital or the international footprint they lacked, and the parent may spend less management time on the larger deal than on the smaller one. The odds of the small firm failing inside a larger organization can run higher than the risk of buying the leader, doing nothing to it, and still owning the leader.

That contradicts conventional wisdom, and the research qualifies that view.

KPMG's study of 682 public-company acquisitions found that relative size on its own was not statistically significant; a clear strategic rationale, thorough due diligence, and acquirer experience mattered more. BCG's 2026 study of nearly 1,300 large public deals found that severe losses concentrate where deal complexity outruns the acquirer's readiness to execute.

Neither says small is safe or large is better. Size interacts with maturity and buyer capability, and a board reading price alone is reading the wrong variable.

Two dimensions explain most of the execution risk: size relative to the acquirer, and the maturity of the target.

• Small and mature is usually the lowest-risk profile, and it is strongest when the buyer has a repeatable playbook.
• Small and immature comes with hidden execution work: professionalization and retention can cost more than the price saved.
• Large and mature is often more executable than it looks, because management depth and working systems reduce day-two firefighting.
• Large and immature is the highest-risk profile, where leverage, premium, and strategic distance compound.

The board runs two tests before the price conversation.

The first is on the target: can it operate without immediate intervention? Does it have a second layer of management, and mature systems and controls? Is the buyer acquiring a business, or an unfinished operating project?

The second is on the buyer: the same acquisition can be manageable for one company and dangerous for another, so the board assesses its own integration routines, governance, retention practices, and management bandwidth against this target.

The board runs both tests to find the hidden second capital commitment. A small purchase price says nothing about the size of the execution project behind it. Management replacement, systems, controls, channel development, working capital, customer stabilization: none of it is in the price, and all of it gets spent. The purchase price is one commitment, but far from the total.

How the buyer intends to hold the business belongs in the same discussion.

In a bear hug, the buyer forces a self-sufficient target into its own model, and on day two the buyer changes the acquired organization. Under a light touch, the buyer agrees in advance to leave management running as long as it hits its targets, with more resources than it had before the deal. A buyer that bear-hugs a standalone-value target damages it; a buyer that only light-touches a combination-value target never captures the value. Make the choice before close and write it down.

This one question governs the whole comparison, and most boards never put it on the agenda: is it better to bet big with confidence, or bet small with low confidence?

Question 6: What survives when the plan doesn't?

Every deal has a base case. At question six, the board asks whether the proposal still makes sense when its weakest assumptions are challenged, including the assumptions about who owns it and how.

The test runs in five parts:

• What must be true for value creation to happen? Name every assumption: market growth, customer retention, channel transfer, founder retention, integration timing, financing, exit multiple.
• Which of those are fragile? Fragile means high consequence plus weak evidence. The most dangerous combination is low detectability plus low reversibility, even when the likelihood is not the highest.
• At what point does the proposal fail? Define the conditions that would make the deal unacceptable financially, strategically, or operationally.
• Is the downside survivable? Can the business and the owner absorb slower growth, delayed gains, leadership departures, a longer hold?
• Can the risk be reshaped? Through price, earnouts, ownership percentage, staging, governance rights, autonomy, or timing.

Some scenarios get run every time: the founder exits within 12 months, second-line management is weaker than expected, the gains from combination take a year longer than planned, the parent has to inject capital during a downturn. If the answers come back as softer versions of the base case, the test has not been run. Those are not downside scenarios. They are the same assumptions with smaller numbers.

Two deals from my time at Teradyne show what the test looks like when it is run.

The first was Universal Robots. The board's initial reaction was that we were not buying a robot company; we had been drawn in by a shiny object. Their concerns were specific. Universal Robots sold to small businesses, which were not our customers. It sold in small quantities at a relatively low price point; we sold 100-unit orders worth millions. It sold entirely through channels, and Teradyne sold direct.

We went back to the board three times. What decided it was not certainty that those concerns were wrong. It was that the target was the clear market leader, with roughly 3,000 units sold, and that it was not a bet-the-company deal. Nobody on the management team would lose their job if it failed.

We decided on survivability, not certainty.

The street loved it. The acquisition paid off. The business also did not scale the way we expected, for exactly the reasons the board named. The board was doing its job.

The second was a 2011 acquisition, a nearly billion-dollar bet, done in cash, with a very different corporate culture. We looked hard at the downside and found it small. The target was highly profitable, its growth had doubled every year, and the base case if nothing improved at all was still acceptable.

The obstacle was not the analysis. It was getting people comfortable with the size.

Ownership is a source of value. It is also a source of risk, and the downside test is where a board finds out which.

The decision

The decision at the end is broader than approving or rejecting the deal, and most boards end up choosing one of the middle four.

• Proceed. The thesis is sound as underwritten.
• Proceed with conditions. On price, financing, governance, autonomy, retention, or integration.
• Stage the commitment. Through a minority position, a partnership, or an option.
• Modify or renegotiate. The path, the buyer, the structure, or the price.
• Delay or remain independent. The right deal at the wrong time is not the right deal.
• Walk away. No deal structure makes a flawed thesis sound.

"Proceed" and "proceed with conditions" both require a written approval record, which is what separates a decision from a vote.

A vote records who was in favor. A record states what the board agreed to, who owns it, and what has to happen before anyone changes course:

• The definition of success from question one, and by when
• The ownership and integration model, bear hug or light touch
• A named owner for each piece of value the deal is supposed to capture
• Leading indicators, and the capital thresholds that trigger a board conversation
• Intervention rights, and the conditions for exit or restructuring

The board reviews performance against those assumptions at the first quarter and at one year, and adjusts. The board's job after approval is not to run the plan. It is to confirm that someone owns it and that the conditions for doubling down, redesigning, or exiting were agreed before they were needed.

Ask while the questions are still cheap

The six questions cost nothing to ask when a growth idea is first raised, but they get expensive later.

Once a banker is engaged, a letter of intent is signed, and a number has been repeated in enough meetings to feel like a fact, the room is committed, and directors hear the questions as obstruction rather than governance.

A director who asks in month one why the company needs to grow at all is doing the board's work. The same question in month six sounds like a vote against the CEO.

A growth decision is sound when four things are true, and each is checkable before the price conversation begins:

• The reason for growing comes from the market, not from a target.
• The path matches where the value comes from.
• The organization can carry the work.
• The downside is survivable.

The next time a deal reaches the board, the first question is not what it costs. It is why the company needs to grow at all, and ask the five follow-on questions.

The board turns to price once those are answered. By then, it knows what it is paying for, who has to deliver it, and what happens if the deal does not deliver.